Detailed Phase IIIb STEP UP trial results presented at the 2025 ADA Scientific Sessions found that an investigational 7.2 mg dose of Wegovy (semaglutide) led to a mean weight loss of 21% in adults ...

In the STEP UP trial, the higher dose of Wegovy® (semaglutide 7.2 mg) demonstrated a mean weight loss of 21%, with a third of participants losing 25% or more of their body weight compared to ...

Higher dose of Wegovy® provided average weight loss of 21% in people with obesity - with a third achieving 25% or more - according to data presented at ADA Results from the phase 3b STEP UP trial ...

Alternatives to weekly injections of weight-loss drugs may be on the way. A monthly dose of a new drug called MariTide helped ...

How does Innovent Biologics' mazdutide, a groundbreaking dual GLP-1/glucagon receptor drug just approved in China, compared to Wegovy and Zepbound? Read more here.

Positive news from the laboratory was the wind beneath the wings of Novo Nordisk (NYSE: NVO) stock on Thursday. The Denmark-based pharmaceutical company, famed for its Ozempic and Wegovy drugs, saw ...

Below are a few more promising studies of weight-loss drugs. Combining bimagrumab, an investigational human monoclonal ...

Full Phase 2 study results showed side effects that led people to stop treatment with MariTide, as well as weight loss ...

Ozempic is a prescription medication made by Novo Nordisk and primarily used to treat patients with type 2 diabetes.

Hims & Hers Health continues to eye personalized services and global expansion. Read more on what investors should know about ...

GoodRx reports GLP-1 weight-loss pills are emerging, with candidates like orforglipron and oral semaglutide likely to gain ...

A monthly weight loss drug from Amgen helped people lose about 20% of their body weight, according to the results of a phase ...